Zydus Life Science , a leading pharmaceutical company, has reported strong financial results for the second quarter ended September 30, 2025, demonstrating significant growth across key business segments.

Financial Highlights

The company delivered consolidated revenues of Rs 61.20 billion, marking a 17% year-on-year increase. Notably, the EBITDA margin improved to 32.90%, a substantial increase of 500 basis points year-on-year. EBITDA stood at Rs 20.20 billion, up 38%, while net profit rose to Rs 12.60 billion, also up 38% compared to the same period last year.

Segment Performance

US Formulations Business

The US formulations business grew 14% to Rs 27.40 billion, driven by volume expansion and new product launches. During the quarter, Zydus filed six ANDAs, received four approvals (including one tentative approval), and launched seven new products.

India Branded Formulations

The branded formulations business in India grew 9% year-on-year, outpacing market growth. The chronic segment continued to drive overall growth, with the company showing faster-than-market growth in key therapies such as cardiology, gynecology, and oncology.

International Markets

The international markets formulations business posted revenues of Rs 7.50 billion, showing strong year-on-year growth of 39%. This growth was broad-based across regions, with robust demand-driven performance in both emerging markets and Europe.

Consumer Wellness

The consumer wellness business recorded revenues of Rs 6.40 billion, up 31% year-on-year. This segment was bolstered by the acquisition of UK-based Comfort Click Limited (CCL), a digital consumer healthcare platform specializing in vitamins, minerals, and supplements.

Key Developments

1. Specialty Portfolio Expansion: In October 2025, Zydus launched Beizray, an albumin-solubilized docetaxel injection, strengthening its 505(b)(2) portfolio in the US market.

2. International Acquisition: The company made its first international acquisition by acquiring Comfort Click Limited, significantly strengthening its presence in key markets of the UK, EU, and the US in the fast-growing vitamins, minerals, and supplements space.

3. Vaccine Innovation: Zydus launched VaxiFlu, India's first trivalent influenza vaccine for flu protection, aligning with global WHO recommendations.

4. Clinical Trial Success: The company reported positive top-line results from the Pivotal EPICS-III Phase 2(b)/3 trial of Saroglitazar Magnesium for Primary Biliary Cholangitis (PBC) in the US market. Zydus is on track to file the new drug application with the US FDA in Q4 FY26.

5. MedTech Expansion: Zydus completed the acquisition of Amplitude Surgical, strengthening its position in the orthopedics space.

Future Outlook

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, commented on the results: "We are pleased with our performance during the quarter and the first half of fiscal '26. The business continued to demonstrate strong growth momentum driven by consistent performance across segments and underpinned by robust operating profitability. We remain committed to accelerating innovation that drives our long-term growth across our businesses."

The company is focusing on expanding its presence in specialty pharmaceuticals, particularly in the US market, and is exploring strategic opportunities in international markets. Zydus is also making strides in the MedTech sector, with plans to expand in focused areas of orthopedics, nephrology, and cardiology.

With a strong pipeline of products and a focus on innovation, Zydus Lifesciences appears well-positioned for sustained growth in the coming quarters.

Zydus Life Science , a prominent Indian pharmaceutical company, has achieved a significant milestone in its global expansion efforts. The company has received its first approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release Capsules, marking a crucial step into the Chinese pharmaceutical market.

Key Highlights

• Product Approved: Venlafaxine Extended-Release Capsules
• Strengths: 75mg and 150mg
• Approving Authority: China's National Medical Products Administration (NMPA)
• Therapeutic Use: Treatment of major depressive disorder and anxiety disorders

Significance of the Approval

This approval represents Zydus Lifesciences' first entry into the Chinese pharmaceutical market through the NMPA regulatory pathway. It opens up new opportunities for the company in one of the world's largest healthcare markets.

About the Medication

Venlafaxine is an antidepressant belonging to a class of medications called serotonin-norepinephrine reuptake inhibitors (SNRIs). The extended-release formulation allows for once-daily dosing, which may improve patient compliance.

Market Implications

This approval may potentially strengthen Zydus Lifesciences' position in the global pharmaceutical industry. The Chinese market, with its large population and growing healthcare needs, presents a significant opportunity for the company to expand its international presence and potentially increase its revenue streams.

While the financial impact of this approval is yet to be determined, it represents a strategic move for Zydus Lifesciences in its global expansion plans. The company's ability to meet the stringent regulatory requirements of the NMPA also speaks to its capabilities in drug development and manufacturing.

As Zydus Lifesciences continues to expand its global footprint, investors and industry observers will likely keep a close watch on how this approval translates into market performance and future opportunities in the Chinese pharmaceutical landscape.